Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.

@article{Stewart1990IntraperitonealYM,
  title={Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.},
  author={J. S. W. Stewart and Vicky Hird and Derek Snook and Babu Dhokia and Gregory B Sivolapenko and Glen Hooker and J Papadimitriou and G Rowlinson and Michael Sullivan and Hannah E. Lambert},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1990},
  volume={8 12},
  pages={
          1941-50
        }
}
  • J. Stewart, V. Hird, +7 authors H. Lambert
  • Published 1990
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
From March 1987 to March 1988, a phase I to II study was carried out in 25 patients with ovarian cancer. They received escalating doses of intraperitoneally (IP) administered yttrium-90 (Y-90)-labeled monoclonal antibody, HMFG1, against a tumor cell-surface antigen. Myelosuppression prevented an escalation of the administered Y-90 activity above 25 mCi. Y-90-labeled antibody was absorbed from the peritoneal cavity into the circulation. Maximum blood Y-90 activity was observed 40 hours after the… Expand
Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.
TLDR
It is concluded that 131I-labeled OC125 can be safely administered ip radioimmunotherapy and Hematologic and gastrointestinal toxicity is predictable and related to the dose and rate of clearance of isotope. Expand
Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
TLDR
MN-14 anti-CEA MAb is a suitable agent for tumor targeting and may have a therapeutic potential in patients with chemotherapy-refractive EOC, especially those with minimal disease. Expand
Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3
TLDR
The results suggest that the observed palliation of ascites is due to prolonged retention of radiolabeled antibody in the peritoneal cavity even in the absence of specific targeting. Expand
A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates.
A pilot study of the treatment of patients with relapsed malignant gliomas with direct intratumoral injections of yttrium-90 (90Y) radioimmunoconjugates has been completed. Patients were recruitedExpand
Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
TLDR
111In-based imaging studies can be used to predict the biodistribution of subsequently administered 90Y-labeled IgM, and further development of radiolabeled AC6C3-2B12 as a diagnostic and therapeutic agent for patients with advanced ovarian carcinoma is warranted. Expand
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
TLDR
This extended phase I-II study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody. Expand
Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.
TLDR
Intraperitoneal RIT with 90Y-labeled 2B12 appears to be an attractive modality to treat peritoneal carcinomatosis and warrants further development. Expand
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
  • R. Alvarez, W. Huh, +10 authors A. Lobuglio
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
This study found that Yttrium-CC49-based RIT in combination with IFN alpha2b and i.p. paclitaxel is feasible and well tolerated at a dose of < or =24.2 mCi/m(2) in this combined regimen. Expand
Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration
TLDR
It is shown that therapeutic tumour doses can be achieved with 131I-cMOv18 IgG in patients with intraperitoneal ovarian cancer lesions with no normal organ toxicity and the i.p. route of administration seems to be preferable to i.v. administration. Expand
Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
TLDR
These data show the excellent tolerability (maximum tolerated dose (MTD) has not been determined yet) and the potential therapeutic role of RIT in advanced ovarian cancer and patients with minimal residual disease would probably take the best advantages of R IT with (90)Y-biotin (electrons). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.
TLDR
In 31 patients with assessable disease there were no responses in 8 patients with gross disease, partial responses in 2 out of 15 patients with nodules less than 2 cms, and complete responses in 3 out of 6 patients with microscopic disease. Expand
Intraperitoneal 131I‐ and 90‐labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry
TLDR
Giving patients intravenous antimouse immunoglobulin to clear 131I‐labelled MAb absorbed from the peritoneal cavity could decrease the toxicity observed in these patients. Expand
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.
TLDR
It is concluded that the intraperitoneal administration of 140 mCi or more of 131I-labeled tumor-associated monoclonal antibodies represents a new and potentially effective form of therapy for patients with small-volume stage III ovarian cancer. Expand
Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody.
TLDR
A limited clinical trial has been conducted with tracer doses (1 mCi) of 90Y in five patients who then received second-look surgery such that tissue samples were obtained for accurate radioactivity quantitation by in vitro counting. Expand
Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
Radiation absorbed-dose estimates and treatment planning are reported for 11 patients with hepatoma who were administered 90Y-labeled polyclonal antiferritin IgG for therapy in a Phase 1-2 trial.Expand
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
TLDR
The efficacy of intracavitary MAb administration as well as the advantage of the concomitant use of intrACavitary and i.p.v. administered MAbs for tumor targeting and for potential MAb guided therapy of metastatic carcinoma are demonstrated. Expand
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms.
TLDR
Although good tumor:non-tumor ratios were obtained with the specific antibodies, the absolute amount of radiolabel detected in tumors was small, and both specific and nonspecific antibodies accumulated in normal lymph nodes to a significant extent. Expand
Radioimmunodetection in patients with suspected ovarian cancer.
TLDR
Twenty-five patients, having either unilateral ovarian tumors of unknown etiology or suspected of having ovarian cancer recurrence were investigated by the method of immunoscintigraphy to rule out primary and/or metastatic tumor sites, with results that correlated with the situation found at the subsequent operation, or by TCT, respectively. Expand
131I‐labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials
TLDR
The scintillation scanning results obtained after iv administration of 131I‐labeled and purified antihuman fibrinogen to 172 consecutive patients with various types of neoplasms show that in 75% of the cases the tumor was unequivocally located. Expand
Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry.
TLDR
Dosimetric studies are reported for four hepatoma patients treated with 131 I-labeled anti-ferritin following combination radiation and chemotherapy, demonstrating tumor-to-liver ratios of about 2:1 for the deposition of radioimmunoglobuBn in these tissues. Expand
...
1
2
3
...